Posters

A Pediatric and Young Adult Phase I Dose Escalation Safety Study of BXQ-350 for Refractory Solid and Central Nervous System Tumors
> View

BXQ-350 targets to the lysosome and kills glioblastoma (GBM) cells via activation of apoptotic caspases in vitro.
> View

Outcomes of High-Grade Glioma Patients in a Phase 1 Trial of BXQ-350, Cancer-selective SapC-DOPS Nanovesicles
> View

First-in-human, First-in-Class Phase 1a Study of BXQ-350 for Solid Tumors and Gliomas
> View

Abstracts

First-in-human, First-in-class Phase 1a Study of BXQ-350 for Solid Tumors and Gliomas.
> View

Absence of Indicators of Hypercoagulability and Anti-phospholipid Syndrome in BXQ-350 First in Human Study.
> View

Allometric Scaling of Preclinical Pharmacokinetic and Toxicokinetic Parameters to Predict Clinical Pharmacokinetics of BXQ-350 Saposin C Protein-Phosphatidylserine Nanovesicles.
> View

Combined Effect of Gemcitabine (GEM) and SapC-DOPS Nanovesicles on Pancreatic Ductal Adenocarcinoma (PDAC) in Mice.
> View

Safety and Pharmacokinetics of BXQ-350 in a Phase 1a and 1b Trial of Solid Tumors and High-grade Glioma.
> View

High-Grade Glioma outcomes in the Phase 1 BXQ-350 trial of cancer-selective SapC-DOPS nanovesicles
> View

Scientific Presentations

Tolerability and Preliminary Efficacy of BXQ-350 for Solid Tumors and Gliomas: First-in-human, first-in-class phase 1 trial

Conflict of Interest Statement: Dr. Rixe holds a minor (<0.01%) equity interest in Bexion Pharmaceuticals, Inc.